DE69613168D1 - Verwendung eines CGRP Antagonisten zur Behandlung von Flechten und Pruritus und so erhaltene Zubereitung - Google Patents

Verwendung eines CGRP Antagonisten zur Behandlung von Flechten und Pruritus und so erhaltene Zubereitung

Info

Publication number
DE69613168D1
DE69613168D1 DE69613168T DE69613168T DE69613168D1 DE 69613168 D1 DE69613168 D1 DE 69613168D1 DE 69613168 T DE69613168 T DE 69613168T DE 69613168 T DE69613168 T DE 69613168T DE 69613168 D1 DE69613168 D1 DE 69613168D1
Authority
DE
Germany
Prior art keywords
lichen
pruritus
preparation
treatment
cgrp antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69613168T
Other languages
English (en)
Other versions
DE69613168T2 (de
DE69613168T3 (de
Inventor
Lacharriere Olivier De
Lionel Breton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9477497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69613168(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LOreal SA filed Critical LOreal SA
Application granted granted Critical
Publication of DE69613168D1 publication Critical patent/DE69613168D1/de
Publication of DE69613168T2 publication Critical patent/DE69613168T2/de
Publication of DE69613168T3 publication Critical patent/DE69613168T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
DE69613168T 1995-03-28 1996-03-04 Verwendung eines CGRP-Antagonisten zur Behandlung von Lichen und Pruritus und erhaltene Zusammensetzung Expired - Lifetime DE69613168T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9503627A FR2732220B1 (fr) 1995-03-28 1995-03-28 Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
FR9503627 1995-03-28

Publications (3)

Publication Number Publication Date
DE69613168D1 true DE69613168D1 (de) 2001-07-12
DE69613168T2 DE69613168T2 (de) 2001-09-27
DE69613168T3 DE69613168T3 (de) 2009-03-05

Family

ID=9477497

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69613168T Expired - Lifetime DE69613168T3 (de) 1995-03-28 1996-03-04 Verwendung eines CGRP-Antagonisten zur Behandlung von Lichen und Pruritus und erhaltene Zusammensetzung

Country Status (14)

Country Link
US (1) US5935586A (de)
EP (1) EP0734728B2 (de)
JP (1) JP3043610B2 (de)
AR (1) AR001435A1 (de)
AT (1) ATE201828T1 (de)
BR (1) BR9601467A (de)
CA (1) CA2172778C (de)
DE (1) DE69613168T3 (de)
ES (1) ES2159697T5 (de)
FR (1) FR2732220B1 (de)
HU (1) HUP9600764A3 (de)
MX (1) MX9601151A (de)
PL (1) PL313511A1 (de)
RU (1) RU2152785C1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958148B1 (en) * 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
JP2001233764A (ja) * 2000-02-22 2001-08-28 Hisamitsu Pharmaceut Co Inc Ｎ−置換−ｏ−トルイジン誘導体からなる鎮痒剤
US11517612B2 (en) 2016-11-18 2022-12-06 Nepsone Ehf Methods of treating inflammatory skin disorders
PL375536A1 (en) 2002-08-12 2005-11-28 Birkir Sveinsson Use of cgrp antagonist compounds for treatment of psoriasis
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
SI2380592T1 (en) 2005-11-14 2018-06-29 Teva Pharmaceuticals International Gmbh The antibody to the calcitonin-related peptide antagonist
CN101959528A (zh) 2008-03-04 2011-01-26 辉瑞有限公司 治疗慢性疼痛的方法
EP3165236B1 (de) 2009-08-28 2022-03-16 Teva Pharmaceuticals International GmbH Verfahren zur behandlung von eingeweideschmerz mittels verabreichung von antagonistischen antikörpern gegen calcitoningen-assoziiertes peptid
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
PE20220337A1 (es) 2014-03-21 2022-03-14 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
KR101593793B1 (ko) * 2014-04-29 2016-02-12 한전케이피에스 주식회사 리프트 행거 및 그 리프트 행거를 사용하여 리프트를 설치하는 방법
KR20220031944A (ko) 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9201425D0 (sv) * 1992-05-06 1992-05-06 Kabi Pharmacia Ab Method and means for preventing constriction of the pupil in the eye
US5445823A (en) * 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith

Also Published As

Publication number Publication date
HUP9600764A2 (en) 1997-06-30
HUP9600764A3 (en) 1998-03-02
ATE201828T1 (de) 2001-06-15
EP0734728B2 (de) 2008-02-13
EP0734728B1 (de) 2001-06-06
HU9600764D0 (en) 1996-05-28
CA2172778A1 (fr) 1996-09-29
JPH08268904A (ja) 1996-10-15
US5935586A (en) 1999-08-10
ES2159697T3 (es) 2001-10-16
RU2152785C1 (ru) 2000-07-20
CA2172778C (fr) 2008-02-12
FR2732220B1 (fr) 1997-04-25
PL313511A1 (en) 1996-09-30
DE69613168T2 (de) 2001-09-27
AR001435A1 (es) 1997-10-22
FR2732220A1 (fr) 1996-10-04
DE69613168T3 (de) 2009-03-05
EP0734728A1 (de) 1996-10-02
MX9601151A (es) 1997-02-28
JP3043610B2 (ja) 2000-05-22
ES2159697T5 (es) 2008-07-01
BR9601467A (pt) 1998-03-31

Similar Documents

Publication Publication Date Title
DE69600399D1 (de) Verwendung von einem CGRP Antagonist für dir Behandlung von Hauterythemen neurogenischen Ursprung und erhaltene Zubearbeitung
DE69622074T2 (de) Cystin-Silikon-Copolymere und deren Verwendung zur Behandlung von keratinischen Materialien
DE69830728D1 (de) Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
ATE256463T1 (de) Pharmazeutische zubereitung zur verwendung in der behandlung von diabetes
ATE331522T1 (de) Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum
DE69720463D1 (de) Sulfonamid-derivate und ihre verwendung zur behandlung von zns-erkrankungen
DE69505657T2 (de) Fluorcarbonetherhybriden enthaltende physiologich akzeptabele emulsionen und verwendungsverfahren
DE69115921D1 (de) Verfahren zur behandlung und verwendung von abfallstoffen
ATA47690A (de) Verfahren und vorrichtung zur bestimmung von gebrauchseigenschaften eines prothesenschaftes
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
DE69613168D1 (de) Verwendung eines CGRP Antagonisten zur Behandlung von Flechten und Pruritus und so erhaltene Zubereitung
DE69635708D1 (de) Tetrandrin zur behandlung von augenentzündungen
DE69432595D1 (de) Antagonisten des angiotensin ii-rezeptors zur behandlung von chronischen entzündlichen erkrankungen
DE69426848D1 (de) Gerät zur Behandlung von lichtempfindlichen Materialien
FI973254A0 (fi) Menetelmä aminoetyylietanoliamiinin ja/tai hydroksietyylipiperatsiinin valmistamiseksi
DE69405919T2 (de) Zusammensetzungen zur Behandlung von Keratinfasern
DE69635977D1 (de) Verfahren zur Bestimmung der therapeutischen Wirkung von Metalloproteinase-Verbindungen, neue Inhibitor-Verbindungen und deren therapeutische Verwendung
DE69420229T2 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
KR960702749A (ko) 심장혈관 질환의 치료를 위한 천연물 및 이와 관련된 합성 화합물의 사용(Use of Natural Products and Related Synthetic Compounds for the Treatment of Cardiovascular Disease)
DE69614739T2 (de) Pflaster zur Behandlung von Pflanzen
MX9101426A (es) Metodo y aparato para perfilar quirurgicamente la cornea empleando vacio
DE69125175D1 (de) Verwendung von angiotensin-ii-rezeptorantagonisten bei der behandlung von atheromen
DE69412178T2 (de) Apparat zur Behandlung von Lagen
DE3586420T2 (de) Verwendung von dihydropyridinen zur behandlung und praevention von arteriosklerose.
ATE360418T1 (de) Verwendung von hydroxypyridon-haltigen puderzubereitungen zur behandlung von unterschenkel- und druckgeschwüren

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings